Hikma Pharmaceuticals Plc Notice of Results (1578R)
February 26 2019 - 6:08AM
UK Regulatory
TIDMHIK
RNS Number : 1578R
Hikma Pharmaceuticals Plc
26 February 2019
London, 26 February 2019 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) will announce its preliminary financial results for the
year ended 31 December 2018 on Wednesday 13 March 2019.
A presentation and webcast for analysts will be held at 9.30am
GMT at the offices of FTI Consulting, 200 Aldersgate, Aldersgate
Street, London, EC1A 4HD, with registration and coffee from
9.15am.
To join via conference call please dial:
UK toll free number: 020 3936 2999
US toll free number: 1 845 709 8568
Standard international access: +44 20 3936 2999
Password: 078263
The results presentation and a webcast recording of the event
will be available on the Company's website at www.hikma.com or
http://webcast.openbriefing.com/hikmaPR2018/.
Playback facility:
A playback of the conference call will be available up to 3
months after the presentation.
UK number: 020 3936 3001
International number: +44 20 3936 3001
Replay PIN code: 685891
-- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 7776
Affairs 477050
Lucinda Baker +44 (0)20 7399 2765/ +44 7818
Deputy Director of Investor Relations 060211
Virginia Spring +44 (0)20 3892 4389/ +44 7973
Senior Investor Relations Manager 679502
FTI Consulting
Ben Atwell/Andrew Ward +44 (0)20 3727 1000
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we're a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,500 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner in the MENA region, and through our
venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit www.hikma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORGMGZZMVVGLZM
(END) Dow Jones Newswires
February 26, 2019 06:08 ET (11:08 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024